Johnson & Johnson MedTech announced that the U.S. Food & Drug Administration has approved the Ottava robotic surgical system investigational device exemption, or IDE, which allows the clinical trial to begin at U.S. sites. The company will now prepare clinical trial sites to receive OTTAVA systems, enroll patients, and begin surgical cases.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- Johnson & Johnson: FDA grants nipocalimab Breakthrough Therapy designation
- Johnson & Johnson submits applications for new indications for Darzalex
- Johnson & Johnson price target raised to $162 from $156 at Guggenheim
- Roblox, Peloton upgraded: Wall Street’s top analyst calls
- Option Care Health downgraded to Neutral at Goldman on Stelara headwinds